| Factor Information | |
|---|---|
| Data ID | 314 |
| Factor | β-TG with Tadalafil administration |
| Description | N/A |
| Biomarker | NA |
| Classification | A6 (clinical factor - other) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | PAH-CHD patients |
| p Value | 0.004 |
| Conclusion | Tadalafil administration was associated with improvement of β-TG level. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 101 |
| CHD Type | isolated CHD |
| CHD Subtype | CHD with PAH |
| Reference | |
|---|---|
| PMID | 30343508 |
| Year | 2019 |
| Title | Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease. |
| Sample | ||
|---|---|---|
| Population | Adolescents and adults | |
| Source | blood | |
| Region | Brazil, Sao Paulo | |
| Method | Student’s t test or the Mann- Whitney test | |
| Race | American | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | Tadalafil group(Treatment) | Sildenafil group(Control) |
| Number | 15 | 16 |
| Age | 30.3 years(19.7-43.1) | 18-50 years |
| Gender (Male: Female) | 3:12 | N/A |
| Marker Level | 332U/mL(319-350) | N/A |
